Hepatic Cell News

Hepatic Cell News is an online resource covering the top research on hepatocytes and liver diseases.

Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis

March 12, 2026

[Gastroenterology] Induction of clusterin and its receptor, low-density lipoprotein receptor-related protein 2, in fibrotic liver was determined using single-cell RNA sequencing and immunofluorescence.

GPR146 in Adipose Tissue Drives Adipose-Liver Crosstalk and Promotes Hepatic Steatosis in Mice

March 12, 2026

[Nature Communications] Researchers identified the orphan G protein-coupled receptor GPR146 as a regulator of hepatic steatosis through adipose–liver crosstalk.

Hepatocyte CEBPA-ORM1 Axis Restricts Alcohol-Associated Liver Disease

March 12, 2026

[Hepatology] Hepatocyte CCAAT/enhancer-binding protein α (CEBPA) was examined for its modulation of alcohol-associated hepatic steatosis and alcohol-associated liver disease.

Lipotoxic Hepatocyte-Derived UBQLN1-Enriched Small Extracellular Vesicles Activate Hepatic Stellate Cells to Promote Hepatic Fibrosis

March 12, 2026

[Autophagy] Scientists elucidated the molecular mechanism by which UBQLN1 (ubiquilin 1) promotes metabolic dysfunction-associated steatohepatitis-related liver fibrosis by regulating small extracellular vesicle secretion and the functionality of the lysosome-mitochondria axis, as well as its clinical significance.

UFMylation Deficiency in Hepatocytes Activates the KEAP1-NRF2 Pathway and Contributes to Hepatocarcinogenesis

March 12, 2026

[Redox Biology] Investigators showed that hepatocyte-specific Ufl1

Integrated Multi-Omics Analysis Reveals that MARCKS Reprograms the Immunosuppressive Microenvironment to Drive Hepatocellular Carcinoma Progression

March 12, 2026

[NPJ Precision Oncology] The authors performed an integrated multi-omics analysis combining bulk transcriptomics, single-cell RNA sequencing, and spatial transcriptomics to systematically investigate the expression pattern and functional relevance of myristoylated alanine-rich C kinase substrate (MARCKS) in HCC.

Zingerone Attenuates Steatosis via Downregulation of AQP9 in Hepatocytes

March 12, 2026

[Naunyn-Schmiedebergs Archives of Pharmacology] Researchers investigated the modulatory effect of ingerone on AQP9 expression in a steatosis cell model through experimental and in silico analyses, providing insights that could contribute to therapeutic interventions for nonalcoholic fatty liver disease.

Mitochondrial Dysfunction in MASH: Focusing on Chronic Inflammation and Intercellular Communication

March 12, 2026

[Biochemical and Biophysical Research Communications] The authors synthesize current literature on mitochondrial dysfunction and chronic inflammation in metabolic dysfunction-associated steatohepatitis/metabolic dysfunction-associated steatotic liver disease (MASH/MASLD), examine the critical role of intrahepatic intercellular communication, particularly via extracellular vesicles, and highlight targeting mitochondria as a promising therapeutic strategy for MASH.

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

March 12, 2026

[Hepion Pharmaceuticals, Inc.] Hepion Pharmaceuticals, Inc. announced that it has in-licensed from Cirna Diagnostics LLC, a novel biomarker assay that detects mutant circulating tumor RNA to facilitate early diagnosis of HCC in high-risk patients.

Five Global Teams Awarded $125 Million to Take on the Toughest Challenges at the Frontiers of Cancer Science

March 6, 2026

[Cancer Grand Challenges (Business Wire)] Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, announced a major $125m commitment to propel cancer research into uncharted territory.

Pilatus Biosciences Receives FDA Fast Track Designation for Metabolic Checkpoint Inhibitor PLT012 in Hepatocellular Carcinoma

February 27, 2026

[Pilatus Biosciences Inc.] Pilatus Biosciences Inc. announced that the US FDA has granted Fast Track designation for PLT012, the company’s first-in-class anti-CD36 monoclonal antibody for the treatment of hepatocellular carcinoma.

RYK Is a GPNMB Receptor That Drives MASH

February 27, 2026

[Nature] Scientists found that systemic or hepatocyte-specific ablation of the gene encoding glycoprotein non-metastatic melanoma protein B (Gpnmb)—a top upregulated gene in metabolic-dysfunction-associated steatohepatitis (MASH)—protected mice from diet-induced MASH.

The publications featured in Hepatic Cell News are expertly selected by our in-house editorial team from high impact, peer-reviewed academic journals. We cover areas including the culturing and characterization of hepatocytes, liver stem cells, and the pathogenesis of conditions such as liver cirrhosis and hepatocellular carcinoma. Additionally, we provide the latest updates on broader news, upcoming events, and job postings to keep the global liver research community connected!